CCR6 and neoplasm: In both mouse and human ovarian cancers, CCR6+ cDCs are recruited massively in the TME through the tumor-derived β-defensins and are induced to become proangiogenic cells, favoring tumor vascularization, and growth in response of tumor VEGF (121).